ProCE Banner Series

Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML

Tune in as leading hematology/oncology pharmacist experts outline the latest data and strategies to best incorporate later-generation TKIs in frontline care of chronic-phase CML. Proper CML monitoring strategies as well as distinguishing characteristics of later-generation TKIs will also be discussed.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of hematology/oncology pharmacists and other healthcare professionals caring for patients with chronic-phase CML.

All Events

Expert Insights for Hematology/Oncology Pharmacists on Later-Generation TKIs as Frontline Therapy in Chronic-Phase CML

Upcoming Events

April

30

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence to optimize the management of patients with chronic-phase CML receiving frontline TKIs. 

Target Audience
This activity has been designed to meet the educational needs of hematology/oncology pharmacists and other healthcare professionals caring for patients with chronic-phase CML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recommend individualized strategies for frontline treatment of chronic-phase CML, based on clinical trial evidence, patient-specific factors, and BCR:ABL1 mutation status
  • Conduct optimal molecular and mutational monitoring during frontline TKI treatment to guide the timing of therapy changes and subsequent therapy decisions in patients with chronic-phase CML
  • Evaluate recent evidence for frontline therapies that may increase the likelihood of treatment-free remission in patients with chronic-phase CML
  • Differentiate important defining characteristics between TKIs and how these attributes may influence frontline efficacy and safety outcomes in chronic-phase CML

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-002-L01-P has been assigned to this live application-based activity (initial release date 04/30/2025). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supported by an educational grant from Novartis Pharmaceuticals Corporation.